Drugs / Tetanus and diptheria toxoids vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00128219 | Jul 2003 → Dec 2008 | group B streptococcal infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus and diptheria toxoids vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00128219 ↗ |
| Known as | Tetanus and Diphtheria Toxoids | “Participants will be randomly assigned to receive the experimental GBS type III vaccine or a licensed vaccine containing Tetanus and Diphtheria Toxoids (Td).” NCT00128219 ↗ |
| Modality | Vaccine | “The control group will receive a single dose of Tetanus and Diphtheria Toxoids (Td) vaccine.” NCT00128219 ↗ |